Catlett Beth, Starr Mitchell, Machalek Dorothy A, Danwilai Thidarat, Palmer Michael, Kelly Andrew, Kaldor John, Dore Gregory J, Darley David, Matthews Gail, Cunningham Philip H
NSW State Reference Laboratory for HIV, St Vincent's Centre for Applied Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
J Clin Virol Plus. 2022 Aug;2(3):100093. doi: 10.1016/j.jcvp.2022.100093. Epub 2022 Jun 24.
Dried blood spot (DBS) specimens are a useful serosurveillance tool particularly in hard-to-reach populations but their application for detecting SARS-CoV-2 infection is poorly characterised.
To compare detection of naturally acquired SARS-CoV-2 antibodies in paired DBS and serum specimens using commercially available serological immunoassays.
Specimens were collected through St Vincent's Hospital observational post COVID-19 cohort study (ADAPT). Laboratory spotted DBS from venepuncture were initially tested on seven assays, a DBS validation completed on three with clinically collected fingerstick DBSs tested on one.
Sensitivity for Euroimmun nucleocapsid (NCP) IgG ELISA from laboratory spotted DBS (n=145), Euroimmun spike, IgG ELISA from laboratory spotted DBS (n=161), and Binding Site total antibody ELISA from clinically collected fingerstick DBS (n=391) was 100% (95% CI: 95.8-100%), 100% (95% CI: 95.8-100%) and 92.9% (95% CI: 89.5-95.5%), respectively. Specificity was 66.2% (95% CI: 53.6-77.0%), 96% (95% CI: 88.7-99.1%) and 98.8% (95% CI: 93.3-99.9%), respectively. All three assays' results displayed a strong positive correlation between DBS compared to paired serum.
The Binding Site™ spike total antibody and Euroimmun™ spike IgG ELISAs provided good analytical performance, demonstrating that DBS specimens could facilitate specimen collection in the epidemiological surveillance of SARS-CoV-2 infection. This is highly applicable in populations and settings where venepuncture is problematic (including community based regional/remote settings, nursing homes, prisons, and schools).
干血斑(DBS)标本是一种有用的血清学监测工具,尤其适用于难以接触到的人群,但其在检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染方面的应用特征尚不明确。
使用市售血清学免疫测定法比较配对的DBS和血清标本中自然获得的SARS-CoV-2抗体的检测情况。
标本通过圣文森特医院COVID-19队列观察性研究(ADAPT)收集。最初对静脉穿刺采集的实验室点样DBS进行了7种检测,对其中3种检测完成了DBS验证,并对1种临床采集的指尖DBS进行了检测。
实验室点样DBS(n = 145)的欧蒙核衣壳(NCP)IgG酶联免疫吸附测定(ELISA)、实验室点样DBS(n = 161)的欧蒙刺突蛋白IgG ELISA以及临床采集的指尖DBS(n = 391)的Binding Site总抗体ELISA的灵敏度分别为100%(95%置信区间:95.8 - 100%)、100%(95%置信区间:95.8 - 100%)和92.9%(95%置信区间:89.5 - 95.5%)。特异性分别为66.2%(95%置信区间:53.6 - 77.0%)、96%(95%置信区间:88.7 - 99.1%)和98.8%(95%置信区间:93.3 - 99.9%)。与配对血清相比,所有三种检测方法的结果在DBS之间均显示出强正相关。
Binding Site™刺突蛋白总抗体和欧蒙™刺突蛋白IgG ELISA具有良好的分析性能,表明DBS标本有助于SARS-CoV-2感染的流行病学监测中的标本采集。这在静脉穿刺存在问题的人群和环境中(包括社区基层地区/偏远地区、养老院、监狱和学校)具有高度适用性。